Earnings summaries and quarterly performance for Iterum Therapeutics.
Executive leadership at Iterum Therapeutics.
Board of directors at Iterum Therapeutics.
Research analysts who have asked questions during Iterum Therapeutics earnings calls.
Recent press releases and 8-K filings for ITRM.
Iterum Therapeutics Reports Q3 2025 Financial Results and Orlyvah Launch Progress
ITRM
Earnings
Product Launch
Guidance Update
- Iterum Therapeutics reported net product sales of $0.4 million for the third quarter of 2025, following the launch of Orlyvah in the United States on August 20, 2025.
- For the full year 2026, the company expects net product revenue to be in a range between $5 million and $15 million and total operating expenses between $25 million and $30 million.
- As of November 12, 2025, Orlyvah has generated over 280 prescriptions from more than 100 unique prescribers, with approximately 40% of prescriptions filled. Payer coverage currently reaches 16% of insured lives, and a rebate agreement has been signed with one of the top three Medicare Part D pharmacy benefit managers for coverage beginning in 2026 or 2027.
- Iterum's cash and cash equivalents of $11 million at the end of September 2025, combined with $2.6 million from an At the Market offering, are expected to fund operations into the second quarter of 2026, with additional capital required to continue commercialization throughout 2026.
Nov 14, 2025, 1:30 PM
Iterum Therapeutics Reports Q3 2025 Financial Results
ITRM
Earnings
Product Launch
Guidance Update
- Iterum Therapeutics plc reported net product revenues of $0.4 million for the third quarter ended September 30, 2025, following the commercial launch of ORLYNVAH™ in the United States in August 2025.
- The company's net loss for Q3 2025 was $9.0 million, compared to a net loss of $6.1 million for the same period in 2024.
- As of September 30, 2025, cash and cash equivalents were $11.0 million, and with an additional $2.6 million raised through November 13, 2025, the company expects to fund operations into the second quarter of 2026.
- Iterum Therapeutics anticipates net product sales of ORLYNVAH™ for 2026 to range between $5 million and $15 million.
Nov 14, 2025, 12:15 PM
Iterum Therapeutics plc Announces At-the-Market Offering and ORLYNVAH™ Launch
ITRM
Product Launch
Guidance Update
- Iterum Therapeutics plc filed a prospectus supplement on October 16, 2025, for an At-the-Market Offering to raise up to an additional $20,000,000 in gross proceeds by offering up to 21,756,057 ordinary shares.
- This offering is conducted under an existing agreement with H.C. Wainwright & Co., LLC, and the company had previously raised approximately $36.2 million through this agreement.
- The company commercially launched its product ORLYNVAH™ into the U.S. community market in August 2025 and anticipates modest sales for the remainder of 2025.
Oct 16, 2025, 9:18 PM
Quarterly earnings call transcripts for Iterum Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more